Mucosal Vaccination with Recombinant Adenovirus Encoding Nucleoprotein Provides Potent Protection against Influenza Virus Infection

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Kim, So Hee ^a   Kim, Joo Young ^a   Choi, Youngjoo ^a   Nguyen, Huan H ^b   Song, Man Ki ^b   Chang, Jun ^a  

^a Ewha Womans University   (South Korea)

^b International Vaccine Institute   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; HERMES ANTIGEN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INFLUENZA VACCINE; RECOMBINANT ADENOVIRUS ENCODING NUCLEOPROTEIN; UNCLASSIFIED DRUG; VIRUS NUCLEOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CROSS REACTION; CYTOTOXIC T LYMPHOCYTE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG POTENCY; DRUG TARGETING; FEMALE; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; INFECTION PREVENTION; INFLUENZA A; INFLUENZA VACCINATION; INFLUENZA VIRUS A; INNATE IMMUNITY; MORTALITY; MOUSE; MUCOSA; NONHUMAN; SURVIVAL; VIRUS REPLICATION; WEIGHT REDUCTION;

ADENOVIRIDAE; ADMINISTRATION, MUCOSAL; ANIMALS; BRONCHOALVEOLAR LAVAGE FLUID; CD8-POSITIVE T-LYMPHOCYTES; DNA PRIMERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEK293 CELLS; HUMANS; IMMUNOGLOBULIN A; INFLUENZA VACCINES; INFLUENZA, HUMAN; MICE; MICE, INBRED BALB C; NUCLEOPROTEINS; VACCINES, SYNTHETIC;

EID: 84884579421     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0075460     Document Type: Article

References (44)

1. Tutykhina IL, Logunov DY, Shcherbinin DN, Shmarov MM, Tukhvatulin AI, et al. (2011) Development of adenoviral vector-based mucosal vaccine against influenza. J Mol Med (Berl) 89: 331-341. doi:10.1007/s00109-010-0696-0. PubMed: 21104066.
2. de Jong JC, Claas EC, Osterhaus AD, Webster RG, Lim WL, (1997) A pandemic warning? Nature 389: 554. doi:10.1038/39221. PubMed: 9335492.
3. Subbarao K, Klimov A, Katz J, Regnery H, Lim W, et al. (1998) Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness. Science 279: 393-396. doi:10.1126/science.279.5349.393. PubMed: 9430591.
4. Dai C, Jiang M, (2013) Understanding H7N9 avian flu. BMJ 346: f2755. doi:10.1136/bmj.f2755. PubMed: 23645899.
5. Chowell G, Echevarría-Zuno S, Viboud C, Simonsen L, Tamerius J, et al. (2011) Characterizing the epidemiology of the 2009 influenza A/H1N1 pandemic in Mexico. PLOS Med 8: e1000436. PubMed: 21629683.
6. Price GE, Soboleski MR, Lo CY, Misplon JA, Quirion MR, et al. (2010) Single-dose mucosal immunization with a candidate universal influenza vaccine provides rapid protection from virulent H5N1, H3N2 and H1N1 viruses. PLOS ONE 5: e13162. doi:10.1371/journal.pone.0013162. PubMed: 20976273.
7. Ulmer JB, Donnelly JJ, Parker SE, Rhodes GH, Felgner PL, et al. (1993) Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 259: 1745-1749. doi:10.1126/science.8456302. PubMed: 8456302.
8. Kreijtz JH, Bodewes R, van Amerongen G, Kuiken T, Fouchier RA, et al. (2007) Primary influenza A virus infection induces cross-protective immunity against a lethal infection with a heterosubtypic virus strain in mice. Vaccine 25: 612-620. doi:10.1016/j.vaccine.2006.08.036. PubMed: 17005299.
9. Lo CY, Wu Z, Misplon JA, Price GE, Pappas C, et al. (2008) Comparison of vaccines for induction of heterosubtypic immunity to influenza A virus: cold-adapted vaccine versus DNA prime-adenovirus boost strategies. Vaccine 26: 2062-2072. PubMed: 18378366.
10. Soboleski MR, Gabbard JD, Price GE, Misplon JA, Lo CY, et al. (2011) Cold-adapted influenza and recombinant adenovirus vaccines induce cross-protective immunity against pH1N1 challenge in mice. PLOS ONE 6: e21937. doi:10.1371/journal.pone.0021937. PubMed: 21789196.
11. Zhou D, Wu TL, Lasaro MO, Latimer BP, Parzych EM, et al. (2010) A universal influenza A vaccine based on adenovirus expressing matrix-2 ectodomain and nucleoprotein protects mice from lethal challenge. Mol Ther 18: 2182-2189. doi:10.1038/mt.2010.202. PubMed: 20877342.
12. Shim BS, Choi JA, Song HH, Park SM, Cheon IS, et al. (2013) Sublingual administration of bacteria-expressed influenza virus hemagglutinin 1 (HA1) induces protection against infection with 2009 pandemic H1N1 influenza virus. J Microbiol 51: 130-135. doi:10.1007/s12275-013-2399-z. PubMed: 23456722.
13. Pedersen GK, Ebensen T, Gjeraker IH, Svindland S, Bredholt G, et al. (2011) Evaluation of the sublingual route for administration of influenza H5N1 virosomes in combination with the bacterial second messenger c-di-GMP. PLOS ONE 6: e26973. doi:10.1371/journal.pone.0026973. PubMed: 22069479.
14. Tretyakova I, Pearce MB, Florese R, Tumpey TM, Pushko P, (2013) Intranasal vaccination with H5, H7 and H9 hemagglutinins co-localized in a virus-like particle protects ferrets from multiple avian influenza viruses. Virology 442: 67-73. doi:10.1016/j.virol.2013.03.027. PubMed: 23618102.
15. He T-C, Zhou S, da Costa LT, Yu J, Kinzler KW, et al. (1998) A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci U S A 95: 2509-2514. doi:10.1073/pnas.95.5.2509. PubMed: 9482916.
16. Kim S, Joo DH, Lee JB, Shim BS, Cheon IS, et al. (2012) Dual role of respiratory syncytial virus glycoprotein fragment as a mucosal immunogen and chemotactic adjuvant. PLOS ONE 7: e32226. doi:10.1371/journal.pone.0032226. PubMed: 22384186.
17. Song JH, Nguyen HH, Cuburu N, Horimoto T, Ko SY, et al. (2008) Sublingual vaccination with influenza virus protects mice against lethal viral infection. Proc Natl Acad Sci U S A 105: 1644-1649. doi:10.1073/pnas.0708684105. PubMed: 18227512.
18. Park MH, Chang J, (2012) Immunogenicity and protective efficacy of a dual subunit vaccine against respiratory syncytial virus and influenza virus. Immune Netw 12: 261-268. doi:10.4110/in.2012.12.6.261. PubMed: 23396871.
19. Zhang J, Tarbet EB, Feng T, Shi Z, Van Kampen KR, et al. (2011) Adenovirus-vectored drug-vaccine duo as a rapid-response tool for conferring seamless protection against influenza. PLOS ONE 6: e22605. doi:10.1371/journal.pone.0022605. PubMed: 21818346.
20. Epstein SL, Kong WP, Misplon JA, Lo CY, Tumpey TM, et al. (2005) Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein. Vaccine 23: 5404-5410. doi:10.1016/j.vaccine.2005.04.047. PubMed: 16011865.
21. Hillaire ML, Osterhaus AD, Rimmelzwaan GF, (2011) Induction of virus-specific cytotoxic T lymphocytes as a basis for the development of broadly protective influenza vaccines. J Biomed Biotechnol, 2011(2011): 939860. PubMed: 22007149.
22. Ahmad R, Sindhu ST, Toma E, Morisset R, Vincelette J, et al. (2001) Evidence for a correlation between antibody-dependent cellular cytotoxicity-mediating anti-HIV-1 antibodies and prognostic predictors of HIV infection. J Clin Immunol 21: 227-233. doi:10.1023/A:1011087132180. PubMed: 11403230.
23. Yewdell JW, Bennink JR, Smith GL, Moss B, (1985) Influenza A virus nucleoprotein is a major target antigen for cross-reactive anti-influenza A virus cytotoxic T lymphocytes. Proc Natl Acad Sci U S A 82: 1785-1789. doi:10.1073/pnas.82.6.1785. PubMed: 3872457.
24. Yewdell JW, Frank E, Gerhard W, (1981) Expression of influenza A virus internal antigens on the surface of infected P815 cells. J Immunol 126: 1814-1819. PubMed: 7217668.
25. Tatsis N, Ertl HC, (2004) Adenoviruses as vaccine vectors. Mol Ther 10: 616-629. doi:10.1016/j.ymthe.2004.07.013. PubMed: 15451446.
26. Van Kampen KR, Shi Z, Gao P, Zhang J, Foster KW, et al. (2005) Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans. Vaccine 23: 1029-1036. doi:10.1016/j.vaccine.2004.07.043. PubMed: 15620476.
27. Kim S, Jang JE, Yu JR, Chang J, (2010) Single mucosal immunization of recombinant adenovirus-based vaccine expressing F1 protein fragment induces protective mucosal immunity against respiratory syncytial virus infection. Vaccine 28: 3801-3808. doi:10.1016/j.vaccine.2010.03.032. PubMed: 20362203.
28. Croyle MA, Patel A, Tran KN, Gray M, Zhang Y, et al. (2008) Nasal delivery of an adenovirus-based vaccine bypasses pre-existing immunity to the vaccine carrier and improves the immune response in mice. PLOS ONE 3: e3548. doi:10.1371/journal.pone.0003548. PubMed: 18958172.
29. Mogensen TH, (2009) Pathogen recognition and inflammatory signaling in innate immune defenses. Clin Microbiol Rev 22: 240-273. doi:10.1128/CMR.00046-08. PubMed: 19366914.
30. Pabst R, Russell MW, Brandtzaeg P, (2008) Tissue distribution of lymphocytes and plasma cells and the role of the gut. Trends Immunol 29: 206-208. doi:10.1016/j.it.2008.02.006. PubMed: 18394963.
31. Plotkin SA, (2008) Vaccines: correlates of vaccine-induced immunity. Clin Infect Dis 47: 401-409. doi:10.1086/589862. PubMed: 18558875.
32. Moldoveanu Z, Clements ML, Prince SJ, Murphy BR, Mestecky J, (1995) Human immune responses to influenza virus vaccines administered by systemic or mucosal routes. Vaccine 13: 1006-1012. doi:10.1016/0264-410X(95)00016-T. PubMed: 8525683.
33. Walker RI, (1994) New strategies for using mucosal vaccination to achieve more effective immunization. Vaccine 12: 387-400. doi:10.1016/0264-410X(94)90112-0. PubMed: 8023545.
34. Wang J, Thorson L, Stokes RW, Santosuosso M, Huygen K, et al. (2004) Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis. J Immunol 173: 6357-6365. PubMed: 15528375.
35. Lemiale F, Kong WP, Akyürek LM, Ling X, Huang Y, et al. (2003) Enhanced mucosal immunoglobulin A response of intranasal adenoviral vector human immunodeficiency virus vaccine and localization in the central nervous system. J Virol 77: 10078-10087. doi:10.1128/JVI.77.18.10078-10087.2003. PubMed: 12941918.
36. Shim BS, Stadler K, Nguyen HH, Yun CH, Kim DW, et al. (2012) Sublingual immunization with recombinant adenovirus encoding SARS-CoV spike protein induces systemic and mucosal immunity without redirection of the virus to the brain. Virol J 9: 215. doi:10.1186/1743-422X-9-215. PubMed: 22995185.
37. van Riet E, Ainai A, Suzuki T, Hasegawa H, (2012) Mucosal IgA responses in influenza virus infections; thoughts for vaccine design. Vaccine 30: 5893-5900. doi:10.1016/j.vaccine.2012.04.109. PubMed: 22835738.
38. Liew FY, Russell SM, Appleyard G, Brand CM, Beale J, (1984) Cross-protection in mice infected with influenza A virus by the respiratory route is correlated with local IgA antibody rather than serum antibody or cytotoxic T cell reactivity. Eur J Immunol 14: 350-356. doi:10.1002/eji.1830140414. PubMed: 6609824.
39. Kurono Y, Yamamoto M, Fujihashi K, Kodama S, Suzuki M, et al. (1999) Nasal immunization induces Haemophilus influenzae-specific Th1 and Th2 responses with mucosal IgA and systemic IgG antibodies for protective immunity. J Infect Dis 180: 122-132. doi:10.1086/314827. PubMed: 10353870.
40. Crowe SR, Turner SJ, Miller SC, Roberts AD, Rappolo RA, et al. (2003) Differential antigen presentation regulates the changing patterns of CD8+ T cell immunodominance in primary and secondary influenza virus infections. J Exp Med 198: 399-410. doi:10.1084/jem.20022151. PubMed: 12885871.
41. Ferguson NM, Galvani AP, Bush RM, (2003) Ecological and immunological determinants of influenza evolution. Nature 422: 428-433. doi:10.1038/nature01509. PubMed: 12660783.
42. Carragher DM, Kaminski DA, Moquin A, Hartson L, Randall TD, (2008) A novel role for non-neutralizing antibodies against nucleoprotein in facilitating resistance to influenza virus. J Immunol 181: 4168-4176. PubMed: 18768874.
43. LaMere MW, Lam HT, Moquin A, Haynes L, Lund FE, et al. (2011) Contributions of antinucleoprotein IgG to heterosubtypic immunity against influenza virus. J Immunol 186: 4331-4339. doi:10.4049/jimmunol.1003057. PubMed: 21357542.
44. El Bakkouri K, Descamps F, De Filette M, Smet A, Festjens E, et al. (2011) Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection. J Immunol 186: 1022-1031. doi:10.4049/jimmunol.0902147. PubMed: 21169548.